Anticancer effect of AZD2461 PARP inhibitor against colon cancer cells carrying wt or dysfunctional p53

Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy

(2020) Stephen A. Jannetti et al.   Frontiers in Pharmacology

The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer

(2020) G. Mauri et al.   ANNALS OF ONCOLOGY

Oncogenic pathways activated by pro-inflammatory cytokines promote mutant p53 stability: clue for novel anticancer therapies

(2020) Gabriella D’Orazi et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Mutant p53, Stabilized by Its Interplay with HSP90, Activates a Positive Feed-Back Loop Between NRF2 and p62 that Induces Chemo-Resistance to Apigenin in Pancreatic Cancer Cells

(2019) Maria Saveria Gilardini Montani et al.   Cancers

Cellular Stress Responses in Radiotherapy

(2019) Kim et al.   Cells

Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer

(2019) Gu Xiao et al.   CANCER RESEARCH

Colorectal cancer

(2019) Evelien Dekker et al.   LANCET

Variable Mutations at the p53-R273 Oncogenic Hotspot Position Leads to Altered Properties

(2019) Ankush Garg et al.   BIOPHYSICAL JOURNAL

Multifaceted Role of PARP-1 in DNA Repair and Inflammation: Pathological and Therapeutic Implications in Cancer and Non-Cancer Diseases

(2019) Simonetta Pazzaglia et al.   Cells

PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside

(2018) Anita A. Turk et al.   CANCER

Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent

(2018) Steven T. Sizemore et al.   MOLECULAR CANCER RESEARCH

PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53

(2018) Qi Liu et al.   ONCOGENE

The comings and goings of PARP-1 in response to DNA damage

(2018) John M. Pascal   DNA REPAIR

Mutant p53 as a guardian of the cancer cell

(2018) Fiamma Mantovani et al.   CELL DEATH AND DIFFERENTIATION

PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines

(2018) Simona Camero et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Mutant p53 establishes targetable tumor dependency by promoting unscheduled replication

(2017) Shilpa Singh et al.   JOURNAL OF CLINICAL INVESTIGATION

PARP-1 inhibitors sensitize HNSCC cells to APR-246 by inactivation of thioredoxin reductase 1 (TrxR1) and promotion of ROS accumulation

(2017) Zhi-Xian Yin et al.   Oncotarget

The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models

(2016) L. Oplustil O'Connor et al.   CANCER RESEARCH

Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4

(2015) Alla Polotskaia et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Synergistic Loss of Prostate Cancer Cell Viability by Coinhibition of HDAC and PARP

(2014) O. S. Chao et al.   MOLECULAR CANCER RESEARCH

Ionizing Radiation-Induced DNA Damage, Response, and Repair

(2013) Wil L. Santivasi et al.   ANTIOXIDANTS & REDOX SIGNALING

DNA Damage Sensing by the ATM and ATR Kinases

(2013) A. Marechal et al.   Cold Spring Harbor Perspectives in Biology

p53-Dependent BRCA1 Nuclear Export Controls Cellular Susceptibility to DNA Damage

(2011) J. Jiang et al.   CANCER RESEARCH

Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent

(2011) Diana Nguyen et al.   CELL CYCLE